PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Representative Training

JANUARY 29, 2025

Biosimilars: The Future of Affordable Biologic Therapies Biologics are some of the most expensive forms of therapy in modern healthcare. The existence of biosimilars is meant to address both the cost and access of biologics in the healthcare industry. [1]

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Medico Reach

OCTOBER 17, 2022

What really matters are the orthopedic medical device trends that are already shaping the healthcare industry. Advancements in medical technology will always be a favorite topic of discussion when analyzing the healthcare sector. million by 2028. Healthcare executives are also looking into AR spinal surgical systems.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Every Ancillary

MAY 14, 2021

Cons: Highly competitive with new options continually emerging. That being said, the clinical laboratory market is expected to see growth of nearly 40% by 2028. Pros: A growing market means a good chance for long-term success with each client. Mostly cash-pay, which means dependable, fast commissions. Opportunities: Liquid Amnion.

Medical sales 52

Medical sales Medical Sales Insurance 52

Clarivate

MAY 31, 2023

According to figures from the Healthcare Research & Data Analytics team at Clarivate, the top three best-selling products for Pfizer, AbbVie, Merck/MSD and Bristol Myers Squibb contributed more than half their revenue in 2022, ranging from 53.3% of AbbVie’s $51.8 billion in revenue to a whopping 67.2% for Bristol Myers Squibb’s $44.7

Pharma 52

Pharma Biopharma Medicine Healthcare 52

Clarivate

AUGUST 27, 2024

In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. ablation market and would have a total global market value of $3 billion.

Marketing 52

Marketing FDA Competition Medical 52

European Pharmaceutical Review

FEBRUARY 7, 2023

However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU. Edward Turtle is a products lawyer, regulatory advisor and litigator with particular experience in the healthcare, technology and consumer product sectors.

Medical 117

Medical Government Marketing Medicine 117

PM360

SEPTEMBER 28, 2022

healthcare system with major implications for the Medicare Advantage and Medicare Part D programs. Although the dynamics within each therapeutic area may vary, certain archetypes could influence competitive dynamics. In this type of class, selecting one product could materially disrupt competitive dynamics.

Manufacturing 97

Manufacturing Government Prescription Marketing 97

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics). In highly competitive categories like diabetes, net price could be half of the list price.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52